Patient-Centric Approaches for Phase I Combination Trials Come on Stage

Other authors

Institut Català de la Salut

Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2023-09-07T12:10:04Z

2023-09-07T12:10:04Z

2023-08-04



Abstract

Combination trials; Cancer


Assajos combinats; Càncer


Ensayos combinados; Cáncer


A disruptive clinical trial design allowed Drilon and colleagues to demonstrate proof of concept of the potential of PF-07284892 to overcome resistance mechanisms to targeted therapies in the clinic.


The authors would like to thank the CaixaResearch Advanced Oncology Research Program supported by Fundació La Caixa (LCF/PR/CE07/50610001).

Document Type

Article


Published version

Language

English

Publisher

American Association for Cancer Research

Related items

Cancer Discovery;13(8)

https://doi.org/10.1158/2159-8290.CD-23-0534

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)